St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014.
The CardioMEMS heart failure system uses a miniaturised, wireless monitoring sensor that is implanted in the pulmonary artery.
Commenting on the acquisition, St Jude Medical chairman, president and chief executive officer Daniel J Starks says, “St Jude Medical’s acquisition of CardioMEMS shows our commitment to providing innovative medical device solutions that reduce the burden of complex diseases like heart failure, both on patients and health care systems. The CardioMEMS heart failure system achieves this goal by setting a new treatment paradigm for heart failure that reduces hospitalisations and improves the quality of life for patients.”
St Jude Medical announced that it will now begin its strategic launch of the CardioMEMS heart failure system in the USA.
The CardioMEMS heart failure system allows clinicians to stabilise pulmonary artery pressures by proactively managing medications and other treatment options while also providing an early indication of worsening heart failure.